Spots Global Cancer Trial Database for escc
Every month we try and update this database with for escc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma | NCT05759325 | Squamous Cell C... | 18 Years - 80 Years | Guangzhou Institute of Respiratory Disease | ||
| Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | NCT05044728 | Non-small Cell ... Esophageal Squa... | Anti-PD-1 antib... Surgical treatm... | 18 Years - 72 Years | Sichuan Cancer Hospital and Research Institute | |
| Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | NCT06339619 | Locally Advance... | Adebrelimab Apatinib Tegafur | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer | NCT04471480 | ESCC | TC/PD-1 inhibit... | 18 Years - 75 Years | Third Military Medical University | |
| Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma | NCT05547828 | ESCC | Tislelizumab co... | 18 Years - 75 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | NCT05462873 | Carcinoma, Non-... Carcinoma, Rena... Esophageal Squa... Squamous Cell C... | QEQ278 | 18 Years - | Novartis | |
| Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | NCT06339619 | Locally Advance... | Adebrelimab Apatinib Tegafur | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | NCT03518554 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma | NCT01240369 | VEGFC Protein i... VEGFC Protein i... VEGFC Protein i... CTTN Protein in... miR326 in ESCC ... | 50 Years - 80 Years | China Medical University Hospital | ||
| Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma | NCT05547828 | ESCC | Tislelizumab co... | 18 Years - 75 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC | NCT05394415 | Esophageal Squa... Tislelizumab Chemoradiation | Tislelizumab Paclitaxel Carboplatin Radiotherapy | 18 Years - 75 Years | Jiangsu Cancer Institute & Hospital | |
| Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | NCT06122493 | Esophageal Squa... | Tirelizumab Nab paclitaxel Carboplatin Radiotherapy | 18 Years - 80 Years | Ruijin Hospital | |
| A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | NCT03518554 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma | NCT05759325 | Squamous Cell C... | 18 Years - 80 Years | Guangzhou Institute of Respiratory Disease | ||
| DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer | NCT05050760 | ESCC | Camrelizumab DCF | 18 Years - 75 Years | Xijing Hospital | |
| S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study | NCT01854749 | Esophageal Squa... | S1 combined wit... | 18 Years - 75 Years | Fudan University | |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | NCT03565003 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer | NCT04471480 | ESCC | TC/PD-1 inhibit... | 18 Years - 75 Years | Third Military Medical University | |
| SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | NCT05022654 | Esophageal Squa... | SI-B001 Irinotecan | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study | NCT01854749 | Esophageal Squa... | S1 combined wit... | 18 Years - 75 Years | Fudan University | |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | NCT03565003 | Non-small Cell ... Head and Neck C... Esophageal Canc... Other Metastati... | JAB-3068 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | NCT04686682 | NSCLC SCLC CRPC ESCC Ovarian Carcino... AML MF Malignant Tumor | JAB-8263 JAB-8263 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A Study of SGN-B6A in Advanced Solid Tumors | NCT04389632 | Carcinoma, Non-... Squamous Cell C... HER2 Negative B... Esophageal Squa... Esophageal Aden... Gastroesophagea... Ovarian Neoplas... Cutaneous Squam... Exocrine Pancre... Urinary Bladder... Uterine Cervica... Stomach Neoplas... | sigvotatug vedo... pembrolizumab cisplatin carboplatin | 18 Years - | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
